Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorCorreia, Eduardo Thadeu de Oliveira-
Autor(es): dc.creatorBarbetta, Letícia Mara dos Santos-
Autor(es): dc.creatorAlmeida, João Paulo Chevrand Latini de-
Autor(es): dc.creatorMesquita, Evandro Tinoco-
Data de aceite: dc.date.accessioned2024-07-11T17:26:22Z-
Data de disponibilização: dc.date.available2024-07-11T17:26:22Z-
Data de envio: dc.date.issued2023-06-06-
Data de envio: dc.date.issued2023-06-06-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttp://app.uff.br/riuff/handle/1/29065-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/750303-
Descrição: dc.descriptionAnakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.-
Descrição: dc.descriptionSim-
Descrição: dc.descriptionAnakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Publicador: dc.publisherTaylor Walker-
Publicador: dc.publisherNiterói, RJ-
Relação: dc.relationJOURNAL OF CARDIOVASCULAR PHARMACOLOGY. Jackson, MS: Taylor Walker, 1979-. Mensal. ISSN: 1533-4023-
Direitos: dc.rightsOpen Access-
Direitos: dc.rightsCC-BY-SA-
Palavras-chave: dc.subjectAnakinra-
Palavras-chave: dc.subjectInterleukin-1 receptor antagonist-
Palavras-chave: dc.subjectRecurrent pericarditis-
Palavras-chave: dc.subjectPericardite-
Palavras-chave: dc.subjectInterleucina-1-
Palavras-chave: dc.subjectAnakinra-
Palavras-chave: dc.subjectInterleukin-1 receptor antagonist-
Palavras-chave: dc.subjectRecurrent pericarditis-
Título: dc.titleAnakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety-
Título: dc.titleAnakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety-
Tipo de arquivo: dc.typeArtigo de periódicos-
Aparece nas coleções:Repositório Institucional da Universidade Federal Fluminense - RiUFF

Não existem arquivos associados a este item.